Suppr超能文献

[5-氟尿嘧啶及其衍生物抗肿瘤活性机制的研究——体内肿瘤生长抑制与胸苷酸合成酶抑制之间的关系]

[Studies on the mechanism of antitumor activity of 5-FU and its derivatives--relationship between the inhibition of tumor growth and the inhibition of thymidylate synthetase in vivo].

作者信息

Nakamura H, Yu-Qin W, Miyauchi S, Nishioka N, Tanaka H, Harada N, Shirasaka T, Fujii S

出版信息

Gan To Kagaku Ryoho. 1984 May;11(5):1049-55.

PMID:6426401
Abstract

The relationship between the antitumor activity and the inhibition of thymidylate synthase after oral administration of 5-FU, FT-207 or UFT was examined. The inhibition of tumor growth on sarcoma-180 after oral administration of 5-FU (20 mg/kg), FT-207 (120 mg/kg) or UFT (30 mg/kg) was 40%, 50% or 70%, respectively. It was found that the inhibition of thymidylate synthase in sarcoma-180 tumor tissue after single oral administration of 5-FU (20 mg/kg), FT-207 (30 or 120 mg/kg) or UFT (30 mg/kg) were about 45%, 20%, 50% or 65%, respectively, but the activities of other enzymes involved in DNA synthesis were not almost inhibited. Thymidylate synthase was inhibited more severely by oral administration of UFT (30 mg/kg). The activities of other enzymes were not inhibited even by continuous oral administration of these drugs for 6 or 11 days. The extent of inhibition of thymidylate synthase seemed to be parallel to that of inhibition of tumor growth. These results suggest that the inhibition of thymidylate synthase by FdUMP converted from 5-FU, FT-207 or UFT plays a major role in their antitumor actions.

摘要

研究了口服5-氟尿嘧啶(5-FU)、替加氟(FT-207)或优福定(UFT)后抗肿瘤活性与胸苷酸合成酶抑制之间的关系。口服5-FU(20mg/kg)、FT-207(120mg/kg)或UFT(30mg/kg)后对肉瘤-180肿瘤生长的抑制率分别为40%、50%或70%。结果发现,单次口服5-FU(20mg/kg)、FT-207(30或120mg/kg)或UFT(30mg/kg)后,肉瘤-180肿瘤组织中胸苷酸合成酶的抑制率分别约为45%、20%、50%或65%,但参与DNA合成的其他酶的活性几乎未受抑制。口服UFT(30mg/kg)对胸苷酸合成酶的抑制作用更强。即使连续口服这些药物6天或11天,其他酶的活性也未受抑制。胸苷酸合成酶的抑制程度似乎与肿瘤生长的抑制程度平行。这些结果表明,由5-FU、FT-207或UFT转化而来的氟尿嘧啶脱氧核苷酸(FdUMP)对胸苷酸合成酶的抑制在它们的抗肿瘤作用中起主要作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验